Submissions

MS Australia’s 2026–27 Pre‑Budget Submission seeks investment to address rising MS prevalence and growing economic impacts. It calls for funding to expand MS research and data infrastructure, increase access to MS Nurses, improve NDIS pricing and planning, strengthen the disability and aged care workforce, and ensure equitable supports for older people with disability. The submission outlines four priority areas: research, nursing, disability reform, and aged care system improvements.

MS Australia’s submission to the inquiry highlights systemic issues in NDIS administration, including inconsistent claims management, inadequate pricing, delayed payments, and disproportionate compliance burdens on registered providers. It calls for clearer pre‑payment rules, risk‑based compliance, improved performance reporting, and a tiered regulatory model. The submission urges the Department to recognise gaps between policy and practice, strengthen two‑way consultation, and address sudden operational changes impacting people with MS and service providers.

MS Australia’s submission to the Department of Infrastructure, Transport, Regional Development, Communications and the Arts advocates for the Transport Standards and guidelines to require regular disability awareness and inclusion training for all public transport staff; procedures for handling equipment disruptions; procedures for crowd management to assist people with disability when boarding and department public transport; and amending Part 15 to prohibit locking accessible toilets, ensuring they remain available for people with disability, including those living with MS.

MS Australia’s submission to the Inquiry into Aged Care Service Delivery highlights the urgent need for equity in aged care for older people with disability, including MS. It calls for immediate release of 20,000 home care packages, alignment of aged care funding with NDIS levels, and inclusion of disability-specific supports in the Support at Home program.

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ocrelizumab (Ocrevus®) via subcutaneous (SC) delivery on the Pharmaceutical Benefits Scheme (PBS) for the treatment of people living with relapsing-remitting multiple sclerosis (RRMS).